



an Open Access Journal by MDPI

## The Impact of Comorbidities on Sarcoidosis

Guest Editor:

### Dr. Claudio Tana

COVID-19 Medicine Unit and  
Geriatrics Clinic, S.S. Annunziata  
Hospital of Chieti, 66100 Chieti,  
Italy

Deadline for manuscript  
submissions:

**closed (30 November 2023)**

### Message from the Guest Editor

Dear Colleagues,

Sarcoidosis is an uncommon disorder characterized by the presence of noncaseating and non-necrotizing granulomas involving all organs almost ubiquitously, although some, such as the lungs, are more affected.

Clinical manifestations are often dominated by lung impairment, but the picture varies depending on the site mainly involved, and nonspecific symptoms can dominate. Some disorders often mimic sarcoidosis; the histopathological features and pathophysiology can overlap and the impact of comorbidities is largely unknown.

A comorbidity can be defined as a medical condition which occurs simultaneously with (correlated or not) another and could influence the patient's outcome. The molecular mechanisms and pathophysiology of this interaction are the current object of study.

The aim of this Special Issue is to report on the most recent advances regarding the impact of comorbidities on sarcoidosis. Both translational research articles and reviews are welcomed, as well as commentaries concerning recent research evidence.

- sarcoidosis
- comorbidity
- genetics
- molecular mechanisms



[mdpi.com/si/120967](https://mdpi.com/si/120967)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI